Literature DB >> 32847864

Evaluation of the Disconnect between Hepatocyte and Microsome Intrinsic Clearance and In Vitro In Vivo Extrapolation Performance.

Beth Williamson1, Stephanie Harlfinger2, Dermot F McGinnity2.   

Abstract

The use of in vitro in vivo extrapolation (IVIVE) from human hepatocyte (HH) and human liver microsome (HLM) stability assays is a widely accepted predictive methodology for human metabolic clearance (CLmet). However, a systematic underprediction of CLmet from both matrices appears to be universally apparent, which can be corrected for via an empirical regression offset. After physiological scaling, intrinsic clearance (CLint) for compounds metabolized via the same enzymatic pathway should be equivalent for both matrices. Compounds demonstrating significantly higher HLM CLint relative to HH CLint have been encountered, raising questions regarding how to predict CLmet for such compounds. Here, we determined the HLM:HH CLint ratio for 140 marketed drugs/compounds, compared this ratio as a function of physiochemical properties and drug metabolism enzyme dependence, and examined methodologies to predict CLmet from both matrices. The majority (78%) of compounds displaying a high HLM:HH CLint ratio were CYP3A substrates. Using HH CLint for CYP3A substrates, the current IVIVE regression offset approach remains an appropriate strategy to predict CLmet (% compounds overpredicted/correctly predicted/underpredicted 27/62/11, respectively). However, using the same approach for HLM significantly overpredicts CLmet for CYP3A substrates (% compounds overpredicted/correctly predicted/underpredicted 56/33/11, respectively), highlighting that a different IVIVE offset is required for CYP3A substrates using HLM. This work furthers the understanding of compound properties associated with a disproportionately high HLM:HH CLint ratio and outlines a successful IVIVE approach for such compounds. SIGNIFICANCE STATEMENT: Oral drug discovery programs typically strive for low clearance compounds to ensure sufficient target engagement. Human liver microsomes and isolated human hepatocytes are used to optimize and predict human hepatic metabolic clearance. After physiological scaling, intrinsic clearance for compounds of the same metabolic pathway should be equivalent between matrices. However, a disconnect in intrinsic clearance is sometimes apparent. The work described attempts to further understand this phenomenon, and by achieving a mechanistic understanding, improvements in clearance predictions may be realized.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2020        PMID: 32847864     DOI: 10.1124/dmd.120.000131

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Multi-task convolutional neural networks for predicting in vitro clearance endpoints from molecular images.

Authors:  Andrés Martínez Mora; Vigneshwari Subramanian; Filip Miljković
Journal:  J Comput Aided Mol Des       Date:  2022-05-27       Impact factor: 4.179

Review 2.  IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making.

Authors:  Xiaoqing Chang; Yu-Mei Tan; David G Allen; Shannon Bell; Paul C Brown; Lauren Browning; Patricia Ceger; Jeffery Gearhart; Pertti J Hakkinen; Shruti V Kabadi; Nicole C Kleinstreuer; Annie Lumen; Joanna Matheson; Alicia Paini; Heather A Pangburn; Elijah J Petersen; Emily N Reinke; Alexandre J S Ribeiro; Nisha Sipes; Lisa M Sweeney; John F Wambaugh; Ronald Wange; Barbara A Wetmore; Moiz Mumtaz
Journal:  Toxics       Date:  2022-05-01

Review 3.  Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization.

Authors:  Jasleen K Sodhi; Leslie Z Benet
Journal:  J Med Chem       Date:  2021-03-25       Impact factor: 7.446

4.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

5.  Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.

Authors:  Christine Wegler; Pär Matsson; Veronica Krogstad; Jozef Urdzik; Hege Christensen; Tommy B Andersson; Per Artursson
Journal:  Mol Pharm       Date:  2021-03-19       Impact factor: 4.939

Review 6.  Metabolic clearance of select opioids and opioid antagonists using hepatic spheroids and recombinant cytochrome P450 enzymes.

Authors:  Wing Y Tuet; Samuel A Pierce; Matthieu Conroy; Justin N Vignola; Justin Tressler; Robert C diTargiani; Bryan J McCranor; Benjamin Wong
Journal:  Pharmacol Res Perspect       Date:  2022-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.